Slides
Page 1
Committed to Maximizing Value for All Shareholders OCTOBER 2026
Page 2
| 2 Healthcare Realty at a Glance Premier Pure-Play Outpatient Medical REIT 33M Owned Sq. Feet 560 Properties BBB/Baa2 S&P/Moody’s Credit Rating ~$750M Annualized Adj. EBITDA $10.6B Enterprise Value 90% Top 50 MSAs $6.2B Market Cap 5.3% Dividend Yield (1) 5.5x Net Debt to Adj. EBITDA (2) Bakersfield MOB (Bakersfield, CA) 2100 Church Street (Nashville, TN) One Scottsdale Medical (Phoenix, AZ) Overlake Medical Pavilion (Seattle, WA) Note: Financial and portfolio information as of September 30, 2026, and market data as of October 23, 2026. Please see the Company’s 3Q 2026 Supplemental report for the quarter ended September 30, 2026 for more information. Source: S&P Capital IQ. (1) Based on annualized dividend of $0.96, and closing share price as of October 23, 2026. (2) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026.
Page 3
| 3 Investment Highlights Only REIT Focused Exclusively on the Outpatient Medical Sector Best-In-Class Portfolio that Posted Market-Leading Same Store NOI Growth Strong Relationships with Leading National and Regional Health Systems Sustained Sector Tailwinds Driving Record Level Occupancy, Rent Escalators and Market Rent Growth Reconstituted Board and Expanded Management Team Committed to Maximizing Value for Shareholders Significantly Improved Balance Sheet with Net Debt to EBITDA(1) at 5.5x and $1.6B of Liquidity (2) Accretive Capital Allocation Opportunities Through Reinvesting into Platform, Growth in Joint Ventures and Select Share Repur chases Compelling Upside Opportunity for Shareholders Through Earnings Growth and the Stock Re -Rating to its Warranted Multiple (1) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026. (2) Liquidity based on cash on hand and unused capacity on Revolving Credit Facility (net of Commercial Paper issuance) and Delay ed Draw Term Loan as of September 30, 2026.
Page 4
SECTION 1 Business Update
Page 5
| 5 3Q 2026 Business Highlights (1) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026. (2) Since the beginning of the second quarter. 3Q Overview Reported Normalized FFO per share of $0.42 Same store cash NOI growth of +5.1% • Tenant retention of 88.0% and +8.6% cash leasing spreads • 80 bps year-over-year increase in Same Store occupancy 1.5M SF of lease executions • Weighted average lease term of 5.9 years with average annual escalators of 3.1% Completed $211M of joint venture acquisitions (~$42M at share) (2) Completed $68M of asset sales, bringing year-to-date disposition activity to $136M ($187M including loan receivable repayments) (2) Repurchased 4.2 million shares at an average price of $17.74 (2) Normalized FFO / Share $0.42 Same Store Cash NOI Growth 5.1% Same Store Occupancy 93.1% Net Debt / Adj. EBITDA (1) 5.5x Financial Results NFFO guidance range of $1.65 – $1.67 Same Store NOI growth range of 5.00% – 5.25% 2026 Revised Guidance
Page 6
| 6 Successfully Executing the Strategic Plan Focused on Leasing Execution and Planning for Future Growth After Completing Phase I of Strategic Plan In Process Complete Phase I “Fix the Company” Invested in new operational talent Introduced Asset Management model aligned with our tenant partners Reduced balance sheet leverage Refined portfolio to our target markets Phase II “Execute, Execute, Execute” Deliver optimal leasing outcomes Record-level retention Regular-way dialogue with health system partners, focused on growth Reduce costs and drive ROI Early Innings Phase III “Disciplined Growth” Deliver new and in-process redevelopments Incremental to Strategic Plan JV acquisitions Opportunistic capital allocation / recycling
Page 7
| 7 5.1% 3.1% 3.1% 2.3% 5.1% 5.4% 5.5% 6.9% 5.1% 5.1% 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 2.9% 3.9% 2.7% 2.3% 3.3% 3.9% 3.7% 4.2% 4.8% 8.6% 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 89.4% 89.9% 89.8% 89.3% 90.0% 91.1% 92.1% 92.3% 92.7% 93.1% 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Strong Operating Performance Reflects Successful Execution of Strategic Plan Higher Occupancy, Stronger Leasing Spreads, Improved Retention, and Sustained NOI Growth Support Operating Momentum 150 – 200+ bps increase since 2Q25310 bps increase since 2Q25 Sustained growth above 5% since 2Q25Consistently delivering mid- to high-80% levels 85.5% 80.5% 81.6% 84.8% 83.1% 88.6% 82.7% 93.5% 88.5% 88.0% 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Implementation of Strategic Plan Implementation of Strategic Plan Implementation of Strategic Plan Implementation of Strategic Plan Same Store Occupancy Same Store Retention Same Store NOI Growth Same Store Cash Leasing Spreads Note: figures based on reported metrics in each quarter.
Page 8
| 8 Disciplined Capital Allocation Capital Allocation Focused On Earnings Accretion and Maximizing Shareholder Value Prioritize financial flexibility through low leverage and high liquidity to enhance optionality within the business • Leverage(1): 5.5x • Liquidity(2): $1.6B Maintain access to wide breadth of capital sources Reduced cost of capital Addressed 2026-2027 maturities and extended weighted average debt tenor Selectively deploy free cash flow and balance sheet capacity into earnings accretive investments Redevelopments: 9 – 12% targeted return on cost Joint venture acquisitions: Enhanced returns through JV fees Year-to-date, announced and/or closed ~$300M of accretive JV acquisitions (~$60M at share) Selectively consider share repurchases when stock is trading at discount to NAV • $175M of shares repurchased in YTD at $17.53 through share buyback program • Additional $75M shares repurchased concurrent with Convertible Note offering Attractive dividend yield of 5.3% (3) based on $0.24 quarterly dividend A Maintain Fortress Balance Sheet B Reinvest in Platform C Return Capital to Shareholders (1) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026. (2) Liquidity based on cash on hand and unused capacity on Revolving Credit Facility (net of Commercial Paper issuance) and Delay ed Draw Term Loan as of September 30, 2026. (3) Based on annualized dividend of $0.96, and closing share price as of October 23, 2026.
Page 9
| 9 Recent Joint Venture Acquisitions Announced and/or Closed ~$300M of Accretive Acquisitions YTD in KKR JV at a Mid-7% Initial Cash Yield (1) Selective Investments into High-Quality, High-Growth Assets Through KKR Joint Venture with a Strong Acquisition Pipeline (1) Represents gross acquisition volumes. HR share of KKR JV is 20%. Summerville MOBs Woodinville Medical CenterPinebrook MOBs MSA: Charleston, SC Close Date: September 2026 Square Feet: 120K Key Tenants: MSA: Tampa, FL Close Date: October 2026 Square Feet: 97K Key Tenants: MSA: Seattle, WA Close Date: October 2026 Square Feet: 33K Key Tenants:
Page 10
| 10 9.0x 10.6x 12.6x 13.8x 14.4x HR (June 2025) HR Current Net Lease REITs Retail REITs Healthcare REITs Value Upside for Healthcare Realty Shareholders Source: Capital IQ as of October 23, 2026. (1) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026. (2) Midpoint of ~$1.65 – ~$1.85 range, per July 2025 Strategic Plan. (3) HR NFFO/sh based on FY2027 consensus estimates and closing share price as of October 23, 2026. (4) Peer set includes: ADC, BNL, EPRT, FCPT, FVR, GNL, GTY, LXP, NNN, NTST, O, STAG, and WPC. (5) Peer set includes: AKR, BRX, CURB, FRT, IVT, KIM, KRG, PECO, REG, and UE. (6) Peer set includes: AHR, ARE, CTRE, CHCT, DOC, JAN, LTC, NHI, OHI, SBRA, UHT, VTR, WELL, and XRN. Excludes DHC and MPW. …But Still Trading at Discount to Peers and Historical AveragesExecuting with Pace and Purpose… Attractive Growth with Demographic Tailwinds, Superior Balance Sheet and High Occupancy / High Margin Business Model (3) 2027 FFOx (4) (6) (5) HR 2.0 Mid-5x 75 – 80% ~$1.75(2) 92% – 93% 65% – 66% 3 – 4% Leverage (1) Payout Ratio NFFO / Share (Year 3 Run-Rate) Total Occupancy NOI Margin SS NOI Growth Fully reduced leverage Right-sized dividend Tracking ahead of schedule 91.2% in Q3’26 64.2% YTD 2026 Exceeding initial growth targets Results
Page 11
| 11 - $300 $500 $1,256 $1,100 $700 - - 2026 2027 2028 2029 2030 2031 2032 2033 2034+ Term Loans (Relationship Banks) Senior Notes RCF / CP New Exchangeable Notes Meaningfully Improved Balance Sheet in 2026 Addressed Near-Term Maturities with Exchangeable Note Offering, Delayed Draw Term Loan and RCF Liquidity S&P / Moody’s Credit Rating BBB / Baa2 Stable Liquidity(1) $1.6B Net Debt to Adj. EBITDA (2) 5.5x Fixed Rate Debt 90% Weighted Avg. Debt Maturity 3.4 years Weighted Avg. Interest Rate 3.1% YTD 2026 Balance Sheet Activity ($M)Key Credit Metrics Note: Financial information as of September 30, 2026. Please see the Company’s 3Q 2026 Supplemental report for the quarter ended September 30, 2026 for more information. Debt maturities shown inclusive of extension options. (1) Liquidity based on cash on hand and unused capacity on Revolving Credit Facility (net of Commercial Paper issuance) and Delay ed Draw Term Loan as of September 30, 2026. (2) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026. 1. Issued $700M Exchangeable Notes due 2032 (3.00% cash coupon) 2. Addressed July 2027 Senior Notes with fully-committed $400M Delayed Draw Term Loan (can be upsized to $500M); 12-month funding option until May 2027 with minimal carry costs 3. Extended $400M of swaps to January 2029 at a fixed SOFR rate of 3.3% 4. Repaid $600M 2026 Senior Unsecured Notes (3.50% cash coupon) 5. New Commercial Paper program representing a ~50bps reduction in short-term borrowing costs 1 2 New $700M Exchangeable Notes $400M Delayed Draw TL 1 2 3 4 5 $950 $100 $306
Page 12
SECTION 1 Company Overview
Page 13
| 13 Premier Outpatient Medical Platform 93.1% 3Q SS Occupancy 5.1% 3Q SS Cash NOI Growth 93% On / Adjacent and Affiliated >5 Years W.A. Lease Term Remaining ~95% Self-Managed Deep Relationships with Leading Health Systems Associated Health Systems by Rank (% of NOI) Concentrated in Top Markets MSA by Rank (% of NOI) Northeast 64 Properties 3.0M SF D.C. Corridor 15 Properties 1.1M SF Atlanta 24 Properties 1.3M SF Miami 10 Properties 0.7M SF Central Florida 28 Properties 1.4M SF Charlotte 31 Properties 1.7M SF Raleigh 27 Properties 1.2M SF San Antonio 10 Properties 0.5M SF Houston 27 Properties 2.1M SFAustin 11 Properties 0.8M SF Dallas / Fort Worth 47 Properties 3.5M SF Phoenix 33 Properties 1.4M SF Southern California 31 Properties 1.9M SF Seattle 27 Properties 1.5M SF Denver Region 42 Properties 2.3M SF Nashville 12 Properties 1.2M SF San Francisco 9 Properties 0.6M SF Charleston 10 Properties 0.4M SF Note: Financial and portfolio information as of September 30, 2026. Southern California includes Los Angeles and San Diego MS As; Northeast includes Albany, New York, Boston, New Haven, and Hartford MSAs; Central Florida includes Tampa, Orlando, and Port Lucie MSAs; Denver Region includes Denver and Colorado Springs MSAs; D.C. Corridor includes Baltimor e and Washington D.C. MSAs.
Page 14
| 14 AA- / Aa2 Key Relationships with Leading Health Systems Top Health System Relationships Select Recent Leasing Transactions 106K SF New Leases / Lease Renewals 2Q 2026 / 3Q 2026 Credit Rating Directly Leased SF (millions) 59K SF New Leases / Lease Renewals 2Q 2026 / 3Q 2026 AA / Aa2 AA+ / Aa1 BBB / Baa2 A+ / A1 A-2 / -- AA / Aa2 AA / Aa2 A- / A3 AA / Aa3 250K+ SF New Leases / Lease Renewals 2Q 2026 / 3Q 2026 59K SF Lease Renewal 3Q 2026 59K SF Lease Renewal 3Q 2026 38K SF Lease Renewals 3Q 2026
Page 15
| 15 Mutually Beneficial Health System Partnerships Virtuous Cycle of Activity with Health Systems Resulting in Accretive Outcomes Ascension Saint Thomas West (Nashville, TN) (Rendering) Health System Overview One of HR’s top 5 health system relationships and a Top 10 U.S. health system (1) Recently completed $4B acquisition of AmSurg Recent Activity HR to invest $35M to modernize three existing Ascension buildings Upgrades to clinical infrastructure, operating rooms, cardiac catheterization labs, and investment into a new Heart and Kidney Transplant Center and a new Thoracic Surgery and Chest & Lung Center Executed over 200K SF of new and renewal leases across three campuses in the greater Nashville market Health System Overview One of HR’s top 5 health system relationships and a Top 10 U.S. health system (1) Occupies space in 37 of HR’s buildings across 5 states Recent Activity Executed ~160K SF of new and renewal leases across 5 states, increasing remaining lease term by 8 years Agreed to sell ~15 acres of non-income producing land to CommonSpirit for $16M, facilitating expansion of existing hospital (2) Retained future MOB development rights Committed tenant improvement allowance for CommonSpirit space upgrades Ascension Midtown (Nashville, TN) (1) Based on 2026 Becker’s Hospital Review (2) Transaction expected to close by the end of 2026 St. Anthony’s Plaza (Denver, CO) McAuley Medical Center (Phoenix, AZ)
Page 16
| 16 Multi-Year Tailwinds Driving Record Sector Performance Outpatient Medical Sector Boosted by Aging Population and Limited New Supply Growth Sector Occupancy(3)Rapid Growth of 65+ Population(1) 60 80 100 120 140 1999 2003 2007 2011 2015 2019 2023 Outpatient Visits Inpatient Admissions 65+ population averages 7 health visits and $20,000 annual spend, more than 2-3x younger generations Sector occupancy reaching highs amidst favorable supply-demand backdrop (1) Source: OECD.org. (2) Patient Visits / Admissions by Year, Indexed to 1999 (Per 1,000 Population). Source: AHA. (3) Source: Revista Top 100 MSAs as of 3Q 2026 Unabated shift in care settings from Hospitals to Outpatient Medical facilities across acuity levels Preference for Outpatient Settings(2) 56 60 64 68 72 76 80 2025 2027 2029 2031 2033 2035 Millions Secular Supply and Demand Tailwinds Have Pushed Sector Occupancy to ~93% 91.5% 91.8% 92.1% 92.4% 92.7% 1Q '23 1Q '24 1Q '25 1Q '26
Page 17
| 17 Strong Backdrop For Elevated Rent Growth Prevailing Rents Today Do Not Justify Cost of New Development, Creating Room to Increase Rent Escalators and CLS (1) Source: RevistaMed Top 100 MSAs as of 3Q 2026. Implied New Construction NNN Rent calculated by the Average Construction Cost / SF multiplied by a Development Yield (spread over Treasuries). Supply Constraints(1) Development starts have declined ~35% since 2022; new starts only ~1% of national inventory 10 12 14 16 18 20 1Q '18 1Q '20 1Q '22 1Q '24 1Q '26 SF (Millions) $636 $300 $350 $400 $450 $500 $550 $600 $650 1Q '23 1Q '24 1Q '25 1Q '26 Rental Rates (PSF, Net)(1)Construction Costs (PSF)(1) Elevated rates, tariffs and other factors have made construction costs PSF higher than ever Implied new construction rents are ~60% higher than existing NNN rates $20 $30 $40 $50 1Q '23 1Q '24 1Q '25 1Q '26 Existing Avg NNN Rent Implied New Construction NNN Rent $40+ $26
Page 18
| 18 4% 3% 2% 2% 2% 3% Outpatient Medical Delivers Stability Across Market Cycles Non-Discretionary Healthcare Utilization and Aging Population Support Stable NOI Growth over the Past 20 Years Source: Green Street Advisors (1) Outpatient medical net operating income change represents Healthcare Realty only. Outpatient Medical Is One of the Only Asset Classes to Maintain Positive Same Store NOI Growth Since the Global Financial Crisis Multi-Family Outpatient Medical (1)OfficeMallIndustrial 4 Years Negative NOI Growth 2 Years Negative NOI Growth 2 Years Negative NOI Growth 4 Years Negative NOI Growth 0 Years Negative NOI Growth Strip Center 2 Years Negative NOI Growth 2%(2%)(11%)(18%)(5%)(5%) Trough Year Performance Since GFC: Stable and Positive Proven Track Record of Stable NOI Growth Average Same Store NOI Growth Since Global Financial Crisis
Page 19
| 19 $0 $5 $10 $15 $20 $25 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 YTD Investment Volume (Billions) Private Markets Recognize Tailwinds and Value in Outpatient Medical Sector Investment Volumes (2015 – 2026) Record Operating Fundamentals and Lower Borrowing Costs Generating Attractive Risk-Adjusted Returns in Outpatient Medical Source: Revista and management observations. Notable Investors Significant Capital Targeting New Investments in the Outpatient Medical Space
Page 20
| 20 Rapid Execution of Healthcare Realty 2.0 Strategic Plan Corporate Governance Organizational Platform Restructuring Portfolio Optimization Reprioritized Capital Allocation Balance Sheet Management Achievements to Date Significant Progress on Strategic Plan with Clear Path to Completion Progress Achieved and maintained mid-5x Net Debt / Adj. EBITDA since 4Q 2025 (2) Issued $700M of Convertible bonds and secured $400M of DDTL to repay $1.1B of 2026 and 2027 Senior Notes Extended Term Loan and Revolving Credit Facility maturities to 2029 and 2030, respectively Moody’s and S&P affirmed Baa2 / BBB ratings with Stable Outlook Completed restructuring of Asset Management platform with new organizational structure and leasing model Achieved target $10M of corporate and property-level G&A savings, bringing G&A in-line with peers Completed ~$1.2B of planned 2025 dispositions at a blended 6.7% cap rate, and exited 14 non-core markets Achieved robust Same Store portfolio NOI growth of 5.7% over the last twelve months (1) Right-sized quarterly dividend to $0.24 / share, saving ~$100M cash flow annually Completed $250M of share buybacks at a meaningful NAV discount Accelerated high-ROI Redevelopments Year-to-date, announced and/or closed ~$300M of accretive JV acquisitions (~$60M at share) Seasoned management team led by new CEO committed to executing Strategic Plan Enhanced talent across the organization in asset management, finance, and technology Reduced size of Board from 12 to 6 members (1) Based on simple average of quarterly reported metrics during period. (2) Net Debt / Annualized Adjusted EBITDA. For more information on the Company’s calculation of leverage, please see the Company’ s 3Q 2026 Supplemental report for the quarter ended September 30, 2026.
Page 21
| 21 Portfolio Optimization Update ~560 Assets Remaining After Completion of Disposition Program (1) Shows approximate figures of portfolio metrics, excludes held for sale assets. (2) Reflects project leased percent of Redevelopments. (3) Approximate annual NOI at time of July 2025 Strategic Plan. Stabilized, high quality assets located in top MSAs with healthy operating performance Identified development and redevelopment projects yielding ~9-12% returns High ROI capital investment opportunities to bring occupancy in line with Stabilized portfolio Description Stabilized (1) ~80% of total portfolio Lease-Up: Unstabilized (1) ~15% of total portfolio Re/Development (1) ~5% of total portfolio # Assets NOI (3) SF Occupancy (3Q 2026) Continue to employ active asset management, maintain high occupancy and tenant retention, and maximize lease economics Execute leasing plans to improve occupancy and NOI Invest capital in Redevelopments at attractive yieldsPortfolio Optimization Approach Portfolio Breakdown (Figures rounded for illustrative purposes) ~460 ~95% Occupancy ~$550M ~25M ~75 ~80% % Leased ~$75M ~6M ~25 ~72%(2) % Leased ~$20M ~2M Stabilized NOI N/A ~$95M ~$50 - 55M Same Store Portfolio
Page 22
SECTION 1 Appendix
Page 23
| 23 Reconciliation of EBITDA (1) Leasing commission amortization is included in the real estate depreciation and amortization add- back for FFO. (2) Includes loss on debt extinguishment, loss on derivatives, and legal fees related to the amended and restated credit facility . (3) Timing adjustments represent a full quarter impact of acquisitions and dispositions. Properties contributed into a joint vent ure are adjusted at the Company's share. Timing adjustments also include non- recurring impacts due to one-time items recognized in the quarter. (4) Includes the pro forma impact of acquisitions and dispositions closed after quarter -end and under contract, as well as share repurchases completed subsequent to quarter -end. ($ in thousands) Three Months Ended September 30, 2026 Net income (loss) ($15,851) Interest expense 44,849 Income taxes 317 Depreciation and amortization (1) 128,101 Unconsolidated JV depreciation, amortization, and interest 7,337 EBITDA $164,753 Transaction costs 1,693 Gain on sales of assets (2,476) Impairments on real estate assets 16,152 Restructuring and severance-related charges 2,031 Debt financing costs (2) 25 Timing impact (3) 1,318 Stock based compensation 4,561 Other (366) Unconsolidated JV adjustments 422 Adjusted EBITDA $188,113 Annualized Adjusted EBITDA $752,452 Debt 4,249,159 Share of Unconsolidated JV Net Debt 31,388 Cash (17,499) Other adjustments(4) (96,585) Net Debt $4,166,463 Net Debt to Adjusted EBITDA 5.5x
Page 24
| 24 Legal Disclaimer This presentation contains disclosures that are “forward-looking statements” relating to Healthcare Realty Trust Incorporated (the “Company”). Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Such risks and uncertainties include, among other things, the following: the Company’s expected results may not be achieved; risks related to future opportunities and plans for the Company, including the uncertainty of expected future financial performance and results of the Company; pandemics or other health crises; variability in interest rates; the availability and cost of capital at expected rates; competition for quality assets; negative developments in the operating results or financial condition of the Company's tenants, including, but not limited to, their ability to pay rent; the Company's ability to reposition or sell facilities with profitable results; the Company's ability to release space at similar rates as vacancies occur; the Company's ability to renew expiring leases; government regulations affecting tenants' Medicare and Medicaid reimbursement rates and operational requirements; unanticipated difficulties and/or expenditures relating to future acquisitions, developments, and redevelopments; changes in rules or practices governing the Company's financial reporting; the Company may be required under purchase options to sell properties and may not be able to reinvest the proceeds from such sales at rates of return equal to the return received on the properties sold; uninsured or underinsured losses related to casualty or liability; the incurrence of impairment charges on its real estate properties or other assets; other legal and operational matters; and other risks and uncertainties affecting the Company, including those described from time to time under the caption “Risk Factors” and elsewhere in the Company’s filings and reports with the Securities and Exchange Commission (the “SEC”), including the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and as may be updated in the Company’s quarterly reports on Form 10-Q filed thereafter. Moreover, other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made, except as required by law. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports.